Commission Directive 2009/150/EC of 27 November 2009 amending Directive 98/8/EC of the European Parliament and of the Council to include flocoumafen as an active substance in Annex I thereto (Text with EEA relevance)

Published date28 November 2009
Subject MatterInternal market - Principles,Approximation of laws,Free movement of goods,Plant health legislation,Environment
Official Gazette PublicationOfficial Journal of the European Union, L 313, 28 November 2009
L_2009313EN.01007501.xml
28.11.2009 EN Official Journal of the European Union L 313/75

COMMISSION DIRECTIVE 2009/150/EC

of 27 November 2009

amending Directive 98/8/EC of the European Parliament and of the Council to include flocoumafen as an active substance in Annex I thereto

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (1), and in particular the second subparagraph of Article 16(2) thereof,

Whereas:

(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (2) establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes flocoumafen.
(2) Pursuant to Regulation (EC) No 1451/2007, flocoumafen has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 14, rodenticides, as defined in Annex V to Directive 98/8/EC.
(3) The Netherlands was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 4 October 2007 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
(4) The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 15 May 2009, in an assessment report.
(5) It appears from the examinations made that biocidal products used as rodenticides and containing flocoumafen may be expected not to present a risk to humans except for accidental incidents with children. A risk has been identified regarding non-target animals. However, flocoumafen is for the time being considered essential for reasons of public health and hygiene. It is therefore justified to include flocoumafen in Annex I, in order to ensure that in all Member States authorisations for biocidal products used as rodenticides and containing flocoumafen can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.
(6) In the light of the findings of the assessment report, it is appropriate to require that specific risk mitigation measures are applied at product authorisation level to products containing flocoumafen and used as rodenticides. Such measures should be aimed at limiting the risk of primary and secondary exposure of humans and non-target animals as well as the long-term effects of the substance on the environment. To this end, certain constraints such as the maximum concentration, the prohibition on marketing the active substance in products which are not ready to use and the use of aversive agents should be imposed across the board, while other conditions should be imposed by the Member States on a case-by-case basis.
(7) In view of the
...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT